Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

15.15 -0.04 (-0.26%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist

Price and Volume

Volume	2,292,560
Open	15.19
Bid (Size)	14.00 (200)
Ask (Size)	15.30 (3,400)
Prev. Close	15.19
Today's Range	15.10 - 15.59
52wk Range	8.980 - 20.76
Shares Outstanding	144,311,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

Today 7:30 EDT

Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers

From Adaptive Biotechnologies

Via GlobeNewswire

Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million ↗

May 26, 2026

Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.

Via The Motley Fool

Performance

YTD	-4.8%	-4.8%
1 Month	+7.9%	+7.9%
3 Month	-8.0%	-8.0%
6 Month	-22.9%	-22.9%
1 Year	+65.6%	+65.6%

More News

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

May 21, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance ↗

May 05, 2026

Via Chartmill

Adaptive Biotechnologies (NASDAQ:ADPT) Reports Strong Q4 Revenue Beat and Path to Profitability ↗

February 05, 2026

Via Chartmill

Adaptive (ADPT) Q1 2026 Earnings Transcript ↗

May 06, 2026

Via The Motley Fool

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

May 05, 2026

Via Chartmill

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

May 05, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors. ↗

May 04, 2026

Via The Motley Fool

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means ↗

April 20, 2026

Via The Motley Fool

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? ↗

April 18, 2026

Via The Motley Fool

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

April 15, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On ↗

April 08, 2026

Via The Motley Fool

Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look ↗

March 30, 2026

Via The Motley Fool

Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year ↗

March 26, 2026

Via The Motley Fool

Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price ↗

March 26, 2026

Via The Motley Fool

Adaptive Biotech (ADPT) Earnings Call Transcript ↗

February 05, 2026

Via The Motley Fool

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

February 05, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

January 27, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

January 22, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Via MarketMinute

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

January 12, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

December 30, 2025

Via MarketMinute

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 30, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

December 15, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Frequently Asked Questions

Is Adaptive Biotechnologies Corporation - Common Stock publicly traded?

Yes, Adaptive Biotechnologies Corporation - Common Stock is publicly traded.

What exchange does Adaptive Biotechnologies Corporation - Common Stock trade on?

Adaptive Biotechnologies Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Adaptive Biotechnologies Corporation - Common Stock?

The ticker symbol for Adaptive Biotechnologies Corporation - Common Stock is ADPT on the Nasdaq Stock Market

What is the current price of Adaptive Biotechnologies Corporation - Common Stock?

The current price of Adaptive Biotechnologies Corporation - Common Stock is 15.15

When was Adaptive Biotechnologies Corporation - Common Stock last traded?

The last trade of Adaptive Biotechnologies Corporation - Common Stock was at 05/29/26 04:00 PM ET

What is the market capitalization of Adaptive Biotechnologies Corporation - Common Stock?

The market capitalization of Adaptive Biotechnologies Corporation - Common Stock is 2.19B

How many shares of Adaptive Biotechnologies Corporation - Common Stock are outstanding?

Adaptive Biotechnologies Corporation - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.